Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -28.75% is 8482% below its 5-year average of -0.33%, near the low end of its 5-year range (-28.75%–49.46%).
19.67% below its 12-month average of -24.02%.
Annual fiscal-year return on assets; no daily interpolation. Historical series through 2025-12-31.
RETURN ON ASSETS (ROA)
-28.75%
RETURN ON ASSETS (ROA) AVG TTM
-24.02%
RETURN ON ASSETS (ROA) AVG 3Y
-10.32%
RETURN ON ASSETS (ROA) AVG 5Y
-0.33%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-19.67%
CURRENT VS 3Y AVG
-178.52%
CURRENT VS 5Y AVG
-8482.09%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
-659.34%
vs the sector median at left
Moderna, Inc.
Market Cap
$53.81B
Return on Assets (ROA)
-28.75%
TTM Avg
-24.02%
3Y Avg
-10.32%
5Y Avg
-0.33%
Market Cap
$56.21B
Return on Assets (ROA)
2.99%
TTM Avg
2.96%
3Y Avg
2.15%
5Y Avg
1.30%
Market Cap
$49.62B
Return on Assets (ROA)
7.25%
TTM Avg
19.91%
3Y Avg
18.29%
5Y Avg
17.04%
Market Cap
$49.54B
Return on Assets (ROA)
1.85%
TTM Avg
3.00%
3Y Avg
3.04%
5Y Avg
2.95%
Market Cap
$62.91B
Return on Assets (ROA)
3.13%
TTM Avg
2.14%
3Y Avg
2.52%
5Y Avg
0.85%
Market Cap
$42.92B
Return on Assets (ROA)
1.77%
TTM Avg
-0.35%
3Y Avg
-1.89%
5Y Avg
-2.43%
Market Cap
$42.30B
Return on Assets (ROA)
4.60%
TTM Avg
4.82%
3Y Avg
4.76%
5Y Avg
4.01%
Market Cap
$40.89B
Return on Assets (ROA)
10.31%
TTM Avg
10.56%
3Y Avg
11.14%
5Y Avg
10.55%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moderna, Inc. (MRNA) | $53.81B | -28.75% | -24.02% | -10.32% | -0.33% |
| Cardinal Health, Inc. (CAH)vs › | $56.21B | 2.99% | 2.96% | 2.15% | 1.30% |
| Edwards Lifesciences Corporation (EW)vs › | $49.62B | 7.25% | 19.91% | 18.29% | 17.04% |
| Becton, Dickinson and Company (BDX)vs › | $49.54B | 1.85% | 3.00% | 3.04% | 2.95% |
| Humana Inc. (HUM)vs › | $48.03B | 2.23% | 2.52% | 4.20% | 5.49% |
| Cencora, Inc. (COR)vs › | $62.91B | 3.13% | 2.14% | 2.52% | 0.85% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.92B | 1.77% | -0.35% | -1.89% | -2.43% |
| IQVIA Holdings Inc. (IQV)vs › | $42.30B | 4.60% | 4.82% | 4.76% | 4.01% |
| Agilent Technologies, Inc. (A)vs › | $40.89B | 10.31% | 10.56% | 11.14% | 10.55% |
| Boston Scientific Corporation (BSX)vs › | $66.83B | 8.11% | 5.66% | 4.50% | 3.49% |
ROA
-28.8%
ROE
-46.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -22.87% |
| 2024-12-31 | -25.18% |
| 2023-12-31 | -25.58% |
| 2022-12-31 | 32.34% |
| 2021-12-31 | 49.46% |
| 2020-12-31 | -10.18% |
| 2019-12-31 | -32.34% |
| 2018-12-31 | -19.61% |
| 2017-12-31 | -23.60% |
| 2016-12-31 | -15.26% |
